CCNB1 and neoplasm: It may downregulate uPA-induced plasmin activation, MMP-2, MMP-9, cyclin A2, cyclin B1, cyclin B2, cyclin E1, phosphorylation of the FAK/paxillin pathway, FASN expression, sex hormone-binding globulin (SHBG), and IGF-binding protein 3 (IGFBP-3) levels and increase cytotoxic effects of chemotherapeutic agents, leading to suppression of cell proliferation, metastasis, migration, cell growth, and tumor progression and promote apoptosis and cell death [38].